These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 18762933)

  • 41. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.
    Anderson GD
    Clin Pharmacokinet; 2005; 44(10):989-1008. PubMed ID: 16176115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Liver Disease on Hepatic Transporter Expression and Function.
    Thakkar N; Slizgi JR; Brouwer KLR
    J Pharm Sci; 2017 Sep; 106(9):2282-2294. PubMed ID: 28465155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment.
    El-Khateeb E; Achour B; Al-Majdoub ZM; Barber J; Rostami-Hodjegan A
    Mol Pharm; 2021 Sep; 18(9):3563-3577. PubMed ID: 34428046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical pharmacokinetics of newer antibacterial agents in liver disease.
    Westphal JF; Brogard JM
    Clin Pharmacokinet; 1993 Jan; 24(1):46-58. PubMed ID: 8448972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of promazine in patients with hepatic cirrhosis--correlation with a novel galactose single point method.
    Hu OY; Tang HS; Sheeng TY; Chen TC; Curry SH
    J Pharm Sci; 1995 Jan; 84(1):111-4. PubMed ID: 7714731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Safe prescribing in patients with liver cirrhosis; 5 pitfalls].
    Weersink RA; Drenth JPH; Ter Borg F; Mulder MB; Taxis K; Borgsteede SD
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic profile of dexloxiglumide.
    Persiani S; D'Amato M; Jakate A; Roy P; Wangsa J; Kapil R; Rovati LC
    Clin Pharmacokinet; 2006; 45(12):1177-88. PubMed ID: 17112294
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
    Li P; Robertson TA; Zhang Q; Fletcher LM; Crawford DH; Weiss M; Roberts MS
    Pharm Res; 2012 Jun; 29(6):1658-69. PubMed ID: 22302523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
    Alcorn J; McNamara PJ
    Clin Pharmacokinet; 2002; 41(13):1077-94. PubMed ID: 12403644
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
    Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
    J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].
    Nomura F; Ohnishi K; Ohto M; Takeda Y; Rikihisa T; Kanakubo Y
    Rinsho Byori; 1991 Oct; 39(10):1093-7. PubMed ID: 1762184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variations of pharmacokinetics of drugs in patients with cirrhosis.
    Pena MA; Horga JF; Zapater P
    Expert Rev Clin Pharmacol; 2016; 9(3):441-58. PubMed ID: 26696448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
    Adedoyin A; Arns PA; Richards WO; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1998 Jul; 64(1):8-17. PubMed ID: 9695714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment.
    El-Khateeb E; Darwich AS; Achour B; Athwal V; Rostami-Hodjegan A
    Aliment Pharmacol Ther; 2021 Aug; 54(4):388-401. PubMed ID: 34218453
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of histamine H2-receptor antagonists on the hepatic elimination of drugs].
    Klotz U; Reimann I
    Klin Wochenschr; 1983 Jul; 61(13):625-32. PubMed ID: 6136626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of ondansetron in patients with hepatic insufficiency.
    Figg WD; Dukes GE; Pritchard JF; Hermann DJ; Lesesne HR; Carson SW; Songer SS; Powell JR; Hak LJ
    J Clin Pharmacol; 1996 Mar; 36(3):206-15. PubMed ID: 8690814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
    Björkman S
    Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
    Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
    Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.